211 related articles for article (PubMed ID: 37586066)
1. Utilization and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Hypertrophic Cardiomyopathy.
Goldstein SA; Kennedy KF; Friedman DJ; Al-Khatib SM; Wang A
J Am Heart Assoc; 2023 Aug; 12(16):e029293. PubMed ID: 37586066
[TBL] [Abstract][Full Text] [Related]
2. Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy-Are there predictors of appropriate therapy?
Weissler-Snir A; Dorian P; Rakowski H; Care M; Spears D
Heart Rhythm; 2021 Jan; 18(1):63-70. PubMed ID: 32800967
[TBL] [Abstract][Full Text] [Related]
3. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.
Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P
JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294
[TBL] [Abstract][Full Text] [Related]
4. Left intraventricular pressure gradient in hypertrophic cardiomyopathy patients receiving implantable cardioverter-defibrillators for primary prevention.
Yazaki K; Suzuki A; Shiga T; Minami Y; Arai K; Ashihara K; Shoda M; Hagiwara N
BMC Cardiovasc Disord; 2021 Feb; 21(1):106. PubMed ID: 33607967
[TBL] [Abstract][Full Text] [Related]
5. Implantable Cardioverter Defibrillator Utilization and Mortality Among Patients ≥65 Years of Age With a Low Ejection Fraction After Coronary Revascularization.
Goldstein SA; Li S; Lu D; Matsouaka RA; Rymer J; Fonarow GC; de Lemos JA; Peterson E; Pokorney SD; Wang T; Al-Khatib SM
Am J Cardiol; 2021 Jan; 138():26-32. PubMed ID: 33068540
[TBL] [Abstract][Full Text] [Related]
6. Device Therapies Among Patients Receiving Primary Prevention Implantable Cardioverter-Defibrillators in the Cardiovascular Research Network.
Greenlee RT; Go AS; Peterson PN; Cassidy-Bushrow AE; Gaber C; Garcia-Montilla R; Glenn KA; Gupta N; Gurwitz JH; Hammill SC; Hayes JJ; Kadish A; Magid DJ; McManus DD; Multerer D; Powers JD; Reifler LM; Reynolds K; Schuger C; Sharma PP; Smith DH; Suits M; Sung SH; Varosy PD; Vidaillet HJ; Masoudi FA
J Am Heart Assoc; 2018 Mar; 7(7):. PubMed ID: 29581222
[TBL] [Abstract][Full Text] [Related]
7. Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study.
Nazer B; Dale Z; Carrassa G; Reza N; Ustunkaya T; Papoutsidakis N; Gray A; Howell SJ; Elman MR; Pieragnoli P; Ricciardi G; Jacoby D; Frankel DS; Owens A; Olivotto I; Heitner SB
Heart Rhythm; 2020 Jul; 17(7):1107-1114. PubMed ID: 32084597
[TBL] [Abstract][Full Text] [Related]
8. Periprocedural Risk and Survival Associated With Implantable Cardioverter-Defibrillator Placement in Older Patients With Advanced Heart Failure.
Fudim M; Ali-Ahmed F; Parzynski CS; Ambrosy AP; Friedman DJ; Pokorney SD; Curtis JP; Fonarow GC; Masoudi FA; Hernandez AF; Al-Khatib SM
JAMA Cardiol; 2020 Jun; 5(6):643-651. PubMed ID: 32211811
[TBL] [Abstract][Full Text] [Related]
9. Comparative Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators in Older Heart Failure Patients With Diabetes Mellitus.
Sharma A; Wu J; Xu H; Hernandez A; Felker GM; Al-Khatib S; Green J; Matsouaka R; Fonarow GC; Singh JP; Heidenreich PA; Ezekowitz JA; DeVore A
J Am Heart Assoc; 2020 Jun; 9(12):e012405. PubMed ID: 32476539
[TBL] [Abstract][Full Text] [Related]
10. Primary prevention of sudden cardiac death in a nonischemic dilated cardiomyopathy population: reappraisal of the role of programmed ventricular stimulation.
Gatzoulis KA; Vouliotis AI; Tsiachris D; Salourou M; Archontakis S; Dilaveris P; Gialernios T; Arsenos P; Karystinos G; Sideris S; Kallikazaros I; Stefanadis C
Circ Arrhythm Electrophysiol; 2013 Jun; 6(3):504-12. PubMed ID: 23588627
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.
Maron BJ; Shen WK; Link MS; Epstein AE; Almquist AK; Daubert JP; Bardy GH; Favale S; Rea RF; Boriani G; Estes NA; Spirito P
N Engl J Med; 2000 Feb; 342(6):365-73. PubMed ID: 10666426
[TBL] [Abstract][Full Text] [Related]
12. [The implantable cardioverter-defibrillator and hypertrophic cardiomyopathy. Experience at three centers].
Marín F; Gimeno JR; Payá E; García-Alberola A; Pérez-Alvarez L; Fernández X; de la Morena G; Sogorb F; Castro-Beiras A; Valdés M; Martínez JG; Monserrat L
Rev Esp Cardiol; 2006 Jun; 59(6):537-44. PubMed ID: 16790196
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy.
Begley DA; Mohiddin SA; Tripodi D; Winkler JB; Fananapazir L
Pacing Clin Electrophysiol; 2003 Sep; 26(9):1887-96. PubMed ID: 12930505
[TBL] [Abstract][Full Text] [Related]
14. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.
Maron BJ; Spirito P; Ackerman MJ; Casey SA; Semsarian C; Estes NA; Shannon KM; Ashley EA; Day SM; Pacileo G; Formisano F; Devoto E; Anastasakis A; Bos JM; Woo A; Autore C; Pass RH; Boriani G; Garberich RF; Almquist AK; Russell MW; Boni L; Berger S; Maron MS; Link MS
J Am Coll Cardiol; 2013 Apr; 61(14):1527-35. PubMed ID: 23500286
[TBL] [Abstract][Full Text] [Related]
15. Association of Obesity With Adverse Long-term Outcomes in Hypertrophic Cardiomyopathy.
Fumagalli C; Maurizi N; Day SM; Ashley EA; Michels M; Colan SD; Jacoby D; Marchionni N; Vincent-Tompkins J; Ho CY; Olivotto I;
JAMA Cardiol; 2020 Jan; 5(1):65-72. PubMed ID: 31693057
[TBL] [Abstract][Full Text] [Related]
16. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy.
Elliott PM; Sharma S; Varnava A; Poloniecki J; Rowland E; McKenna WJ
J Am Coll Cardiol; 1999 May; 33(6):1596-601. PubMed ID: 10334430
[TBL] [Abstract][Full Text] [Related]
17. Association of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic Cardiomyopathy.
Eberly LA; Day SM; Ashley EA; Jacoby DL; Jefferies JL; Colan SD; Rossano JW; Semsarian C; Pereira AC; Olivotto I; Ingles J; Seidman CE; Channaoui N; Cirino AL; Han L; Ho CY; Lakdawala NK
JAMA Cardiol; 2020 Jan; 5(1):83-91. PubMed ID: 31799990
[TBL] [Abstract][Full Text] [Related]
18. Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy.
Nauffal V; Marstrand P; Han L; Parikh VN; Helms AS; Ingles J; Jacoby D; Lakdawala NK; Kapur S; Michels M; Owens AT; Ashley EA; Pereira AC; Rossano JW; Saberi S; Semsarian C; Ware JS; Wittekind SG; Day S; Olivotto I; Ho CY
Eur Heart J; 2021 Oct; 42(38):3932-3944. PubMed ID: 34491319
[TBL] [Abstract][Full Text] [Related]
19. Mortality Implications of Appropriate Implantable Cardioverter Defibrillator Therapy in Secondary Prevention Patients: Contrasting Mortality in Primary Prevention Patients From a Prospective Population-Based Registry.
Almehmadi F; Porta-Sánchez A; Ha ACT; Fischer HD; Wang X; Austin PC; Lee DS; Nanthakumar K
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862957
[TBL] [Abstract][Full Text] [Related]
20. Prognosis of patients with hypertrophic cardiomyopathy and low-normal left ventricular ejection fraction.
Choi YJ; Kim HK; Hwang IC; Park CS; Rhee TM; Lee HJ; Park JB; Yoon YE; Lee SP; Cho GY; Kim YJ
Heart; 2023 Apr; 109(10):771-778. PubMed ID: 36581445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
